Back to News
Dec 26, 2025 8:40 AM

RNA drug developer Ribo Passes Hong Kong Listing Hearing, Kicking Off IPO

Leading RNA drug developer Suzhou Ribo Life Science Co. Ltd. passed its hearing for a listing on the Hong Kong Stock Exchange, marking the official launch of its IPO, according to its post-hearing information pack released on Sunday on the exchange's website.

According to its latest prospectus, Ribo's revenue rose 56.6% to 103.8 million yuan ($14.7 million) in the first six months of this year from 66.3 million yuan a year earlier. Its loss over that time narrowed to 97.8 million yuan from 141.6 million yuan a year earlier.

Founded in 2007 ...